Fatty acid oxidation inhibitors

Fatty acid oxidation inhibitors are a new potent class of drugs used in treatment of stable angina pectoris and an addition in treatment of chronic heart failure.

Drugs

CPT-I inhibitors: Etomoxir, Oxfenicine, Perhexiline
CPT-I (carnitine palmitoyl transferase) converts fatty acyl-CoA to fatty acyl-carnitine.
Carnitine biosynthesis inhibitor: Mildronate^[1]
3-KAT inhibitors: Trimetazidine
3-KAT (3-ketoacyl-coenzyme A thiolase) inhibitors directly inhibits fatty acid beta-oxidation.
pFOX (partial fatty acid oxidation inhibitors): Ranolazine
pFOX directly inhibits fatty acid beta-oxidation.^[2]

References

↑ Liepinsh, E; Vilskersts, R; Loca, D; et al. (December 2006). "Mildronate, an inhibitor of carnitine biosynthesis, induces an increase in gamma-butyrobetaine contents and cardioprotection in isolated rat heart infarction". J. Cardiovasc. Pharmacol. 48: 314–9. doi:10.1097/01.fjc.0000250077.07702.23. PMID 17204911.
↑ Partial fatty acid oxidation inhibitors: a potentially new class of drugs for heart failure; European Journal of Heart Failure 4 2002. 3-6; http://eurjhf.oxfordjournals.org/content/4/1/3.full.pdf+html

This article is issued from Wikipedia - version of the 6/12/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.